MARSHALL & POPP, LLC for AMGEN USA INC.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues related to prescription drug value. Issues related to supply chain and Buy America requirements. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19/S.3129: Lower Costs, More Cures Act of 2019. Biosimilars. 340B issues. Patents and protection of intellectual property issues. Issues related to the COVID-19 pandemic, including patient access of Part B drugs. H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act. S.4775: Delivering Immediate Relief to America's Families, Schools and Small Businesses Act. Issues related to the end stage renal disease (ESRD) prospective payment system (PPS) proposed rule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HAZEN CLAY MARSHALL | Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles |
| MONICA POPP | Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.